Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,376,846
  • Shares Outstanding, K 118,017
  • Annual Sales, $ 1,015 M
  • Annual Income, $ 444,090 K
  • EBIT $ 808 M
  • EBITDA $ 886 M
  • 60-Month Beta 0.97
  • Price/Sales 6.09
  • Price/Cash Flow 15.10
  • Price/Book 173.55

Options Overview Details

View History
  • Implied Volatility 35.07% (+0.66%)
  • Historical Volatility 40.73%
  • IV Percentile 25%
  • IV Rank 19.08%
  • IV High 59.09% on 04/04/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 25) 4.59 (6.47%)
  • Put/Call Vol Ratio 1.89
  • Today's Volume 55
  • Volume Avg (30-Day) 773
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 13,241
  • Open Int (30-Day) 13,079
  • Expected Range 66.39 to 75.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.55
  • Number of Estimates 4
  • High Estimate 1.70
  • Low Estimate 1.42
  • Prior Year 1.03
  • Growth Rate Est. (year over year) +50.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.85 +3.09%
on 01/26/26
82.22 -13.68%
on 02/09/26
+1.75 (+2.54%)
since 01/23/26
3-Month
61.22 +15.92%
on 12/11/25
82.22 -13.68%
on 02/09/26
+0.64 (+0.90%)
since 11/21/25
52-Week
47.50 +49.42%
on 05/14/25
82.22 -13.68%
on 02/09/26
+13.22 (+22.90%)
since 02/21/25

Most Recent Stories

More News
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

HALO : 70.42 (-0.79%)
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 70.42 (-0.79%)
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million

HALO : 70.42 (-0.79%)
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

ACHC : 16.89 (+0.60%)
HIMS : 15.57 (-0.38%)
PRVA : 21.95 (-0.18%)
HALO : 70.42 (-0.79%)
RDNT : 70.08 (-0.83%)
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

SAN DIEGO , Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results...

HALO : 70.42 (-0.79%)
3 Small-Cap Stocks with Solid Fundamentals

3 Small-Cap Stocks with Solid Fundamentals

AWI : 196.38 (-1.28%)
HALO : 70.42 (-0.79%)
WBTN : 11.01 (-1.43%)
3 Growth Stocks Set to Flourish

3 Growth Stocks Set to Flourish

ARES : 116.79 (-5.17%)
VRT : 241.83 (-0.79%)
HALO : 70.42 (-0.79%)
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of  $1,385 - $1,400 million, YoY Growth of 36% to 38% 1 - Royalty Revenue of $865 - $870...

HALO : 70.42 (-0.79%)
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update

SAN DIEGO , Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30...

HALO : 70.42 (-0.79%)
Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

HALO : 70.42 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 74.44
2nd Resistance Point 73.58
1st Resistance Point 72.28
Last Price 70.42
1st Support Level 70.12
2nd Support Level 69.26
3rd Support Level 67.96

See More

52-Week High 82.22
Last Price 70.42
Fibonacci 61.8% 68.96
Fibonacci 50% 64.86
Fibonacci 38.2% 60.76
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar